Literature DB >> 17498082

ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.

M A Sahud1, K P Pratt, O Zhukov, K Qu, A R Thompson.   

Abstract

Inhibitors of FVIII are usually IgG polyclonal antibodies that develop as alloimmune responses in patients with congenital haemophilia A or as autoimmune responses resulting in acquired haemophilia. Their recognition can be difficult, especially when the titre is low. Furthermore, results from a Bethesda assay often require several days as samples are referred to a specialty laboratory. The aim of this study is to assess the utility of an ELISA system for detecting immune responses to FVIII. A total of 246 plasma samples submitted from 176 individuals with immune responses to FVIII, as verified with the Bethesda assay, and samples from 50 control subjects were tested for the presence of FVIII-specific IgG using an ELISA-based assay. Paired sera from 18 of the patients were also tested by the ELISA. Of the 246 samples that were positive for a FVIII inhibitor by the Bethesda assay, 235 (95.5%) were also positive by ELISA. The regression coefficient, using Log BU was r = 0.82. The correlation data were strengthened when 27 inhibitor samples were diluted further. There was a strong correlation between ELISA results for the 18-paired serum and plasma samples (r = 0.99). There is a strong correlation between the ELISA and Bethesda methods in detecting immune responses to FVIII. The ELISA provides rapid screening that could be available well in advance of confirmation by the Bethesda assay.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498082     DOI: 10.1111/j.1365-2516.2007.01450.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

2.  Rare case of acquired haemophilia and lupus anticoagulant.

Authors:  Devika Gupta; Tathagat Chatterjee; Ajay Sharma; Prosenjit Ganguli; Satyaranjan Das; Sanjeevan Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-09       Impact factor: 0.900

Review 3.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

4.  Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia A follow-up.

Authors:  Albain Chansavang; Aurélien Philippe; Ines Bozinovic; Khalil Ben Hadj Ali; David Smadja; Dominique Helley; Luc Darnige; Laetitia Mauge
Journal:  Ann Hematol       Date:  2022-09-20       Impact factor: 4.030

5.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

Review 6.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

7.  Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog.

Authors:  Stephanie Planque; Miguel A Escobar; Keri C Smith; Hiroaki Taguchi; Yasuhiro Nishiyama; Elizabeth Donnachie; Kathleen P Pratt; Sudhir Paul
Journal:  J Biol Chem       Date:  2008-03-11       Impact factor: 5.157

8.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.

Authors:  Angela Huth-Kühne; Francesco Baudo; Peter Collins; Jørgen Ingerslev; Craig M Kessler; Hervé Lévesque; Maria Eva Mingot Castellano; Midori Shima; Jean St-Louis
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

9.  Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.

Authors:  Hongbing Ma; Hong Chang
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

10.  Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance.

Authors:  Kenneth B Lewis; Richard J Hughes; Melinda S Epstein; Neil C Josephson; Christine L Kempton; Craig M Kessler; Nigel S Key; Tom E Howard; Rebecca Kruse-Jarres; Jeanne M Lusher; Christopher E Walsh; Raymond G Watts; Ruth A Ettinger; Kathleen P Pratt
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.